(Q34589227)

English

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

author name string

Ruud P M Dings

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Emily S Van Laar

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Jeremy Webber

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Yan Zhang

4

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Robert J Griffin

5

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Stephen J Waters

6

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

John R MacDonald

7

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Kevin H Mayo

8

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

language of work or name

0 references

publication date

1 April 2008

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

265

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

270-280

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

A journey in structure-based drug discovery: from designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

NMR solution structure of the angiostatic peptide anginex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Anti-angiogenesis and anti-tumor activity of recombinant anginex.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Galectin-1: a small protein with major functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Galectin-1 as a potential cancer target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Angiostatic peptides use plasma fibronectin to home to angiogenic vasculature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

ATM-dependent CHK2 activation induced by anticancer agent, irofulven

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Expression of galectins in cancer: a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Galectin-1: a bifunctional regulator of cellular proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Design of a partial peptide mimetic of anginex with antiangiogenic and anticancer activity.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptide

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Irofulven (MGI Pharma).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

The designer anti-angiogenic peptide anginex targets tumor endothelial cells and inhibits tumor growth in animal models.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Recent advances in the treatment of epithelial ovarian cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Anginex, a designed peptide that inhibits angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Preclinical antitumor activity of 6-hydroxymethylacylfulvene, a semisynthetic derivative of the mushroom toxin illudin S.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Galectins: a family of animal beta-galactoside-binding lectins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Response of the FSaII fibrosarcoma to antiangiogenic modulators plus cytotoxic agents.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Two distinct classes of carbohydrate-recognition domains in animal lectins

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Role of galaptin in ovarian carcinoma adhesion to extracellular matrix in vitro

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Lactose-binding lectin expression in human colorectal carcinomas. Relation to tumor progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

7 July 2018

Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

27 October 2018

Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

27 October 2018

Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

27 October 2018

Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3042303

27 October 2018

Localization of endogenous lectins in normal human breast, benign breast lesions and mammary carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ovarian cancer chemotherapy: carboplatin as standard

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis treatment, new concepts on the horizon

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antiangiogenesis therapy using a novel angiogenesis inhibitor, anginex, following radiation causes tumor growth delay

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anti-tumor activity of the novel angiogenesis inhibitor anginex

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18378392

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.CANLET.2008.02.048

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34589227&oldid=1595220350"